<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <!-- common.css -->
  <style>* {-webkit-tap-highlight-color: rgba(0,0,0,0);}html {-webkit-text-size-adjust: none;}body {font-family: Arial, Helvetica, sans-serif;margin: 0;color: #333;word-wrap: break-word;}h1, h2, h3, h4, h5, h6 {line-height: 1.1;}img {max-width: 100% !important;}blockquote {margin: 0;padding: 0 15px;color: #777;border-left: 4px solid #ddd;}hr {background-color: #ddd;border: 0;height: 1px;margin: 15px 0;}code {font-family: Menlo, Consolas, 'Ubuntu Mono', Monaco, 'source-code-pro', monospace;line-height: 1.4;margin: 0;padding: 0.2em 0;font-size: 85%;background-color: rgba(0,0,0,0.04);border-radius: 3px;}pre {margin: 0;}pre > code {margin: 0;padding: 0;font-size: 100%;word-break: normal;background: transparent;border: 0;}ol {list-style-type: decimal;}ol ol, ul ol {list-style-type: lower-latin;}ol ol ol, ul ol ol, ul ul ol, ol ul ol {list-style-type: lower-roman;}table {border-spacing: 0;border-collapse: collapse;margin-top: 0;margin-bottom: 16px;}table th {font-weight: bold;}table th, table td {padding: 6px 13px;border: 1px solid #ddd;}table tr {border-top: 1px solid #ccc;}table tr:nth-child(even) {background-color: #f8f8f8;}input[type="checkbox"] {cursor: default;margin-right: 0.5em;font-size: 13px;}.task-list-item {list-style-type: none;}.task-list-item+.task-list-item {margin-top: 3px;}.task-list-item input {float: left;margin: 0.3em 1em 0.25em -1.6em;vertical-align: middle;}#tag-field {margin: 8px 2px 10px;}#tag-field .tag {display: inline-block;background: #cadff3;border-radius: 4px;padding: 1px 8px;color: black;font-size: 12px;margin-right: 10px;line-height: 1.4;}</style>
  <!-- ace-static.css -->
  <style>.ace_static_highlight {white-space: pre-wrap;}.ace_static_highlight .ace_gutter {width: 2em;text-align: right;padding: 0 3px 0 0;margin-right: 3px;}.ace_static_highlight.ace_show_gutter .ace_line {padding-left: 2.6em;}.ace_static_highlight .ace_line {position: relative;}.ace_static_highlight .ace_gutter-cell {-moz-user-select: -moz-none;-khtml-user-select: none;-webkit-user-select: none;user-select: none;top: 0;bottom: 0;left: 0;position: absolute;}.ace_static_highlight .ace_gutter-cell:before {content: counter(ace_line, decimal);counter-increment: ace_line;}.ace_static_highlight {counter-reset: ace_line;}</style>
  <style>.ace-chrome .ace_gutter {background: #ebebeb;color: #333;overflow : hidden;}.ace-chrome .ace_print-margin {width: 1px;background: #e8e8e8;}.ace-chrome {background-color: #FFFFFF;color: black;}.ace-chrome .ace_cursor {color: black;}.ace-chrome .ace_invisible {color: rgb(191, 191, 191);}.ace-chrome .ace_constant.ace_buildin {color: rgb(88, 72, 246);}.ace-chrome .ace_constant.ace_language {color: rgb(88, 92, 246);}.ace-chrome .ace_constant.ace_library {color: rgb(6, 150, 14);}.ace-chrome .ace_invalid {background-color: rgb(153, 0, 0);color: white;}.ace-chrome .ace_fold {}.ace-chrome .ace_support.ace_function {color: rgb(60, 76, 114);}.ace-chrome .ace_support.ace_constant {color: rgb(6, 150, 14);}.ace-chrome .ace_support.ace_type,.ace-chrome .ace_support.ace_class.ace-chrome .ace_support.ace_other {color: rgb(109, 121, 222);}.ace-chrome .ace_variable.ace_parameter {font-style:italic;color:#FD971F;}.ace-chrome .ace_keyword.ace_operator {color: rgb(104, 118, 135);}.ace-chrome .ace_comment {color: #236e24;}.ace-chrome .ace_comment.ace_doc {color: #236e24;}.ace-chrome .ace_comment.ace_doc.ace_tag {color: #236e24;}.ace-chrome .ace_constant.ace_numeric {color: rgb(0, 0, 205);}.ace-chrome .ace_variable {color: rgb(49, 132, 149);}.ace-chrome .ace_xml-pe {color: rgb(104, 104, 91);}.ace-chrome .ace_entity.ace_name.ace_function {color: #0000A2;}.ace-chrome .ace_heading {color: rgb(12, 7, 255);}.ace-chrome .ace_list {color:rgb(185, 6, 144);}.ace-chrome .ace_marker-layer .ace_selection {background: rgb(181, 213, 255);}.ace-chrome .ace_marker-layer .ace_step {background: rgb(252, 255, 0);}.ace-chrome .ace_marker-layer .ace_stack {background: rgb(164, 229, 101);}.ace-chrome .ace_marker-layer .ace_bracket {margin: -1px 0 0 -1px;border: 1px solid rgb(192, 192, 192);}.ace-chrome .ace_marker-layer .ace_active-line {background: rgba(0, 0, 0, 0.07);}.ace-chrome .ace_gutter-active-line {background-color : #dcdcdc;}.ace-chrome .ace_marker-layer .ace_selected-word {background: rgb(250, 250, 255);border: 1px solid rgb(200, 200, 250);}.ace-chrome .ace_storage,.ace-chrome .ace_keyword,.ace-chrome .ace_meta.ace_tag {color: rgb(147, 15, 128);}.ace-chrome .ace_string.ace_regex {color: rgb(255, 0, 0)}.ace-chrome .ace_string {color: #1A1AA6;}.ace-chrome .ace_entity.ace_other.ace_attribute-name {color: #994409;}.ace-chrome .ace_indent-guide {background: url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAAE0lEQVQImWP4////f4bLly//BwAmVgd1/w11/gAAAABJRU5ErkJggg==") right repeat-y;}</style>
  <!-- export.css -->
  <style>
    body{margin:0 auto;max-width:800px;line-height:1.4}
    #nav{margin:5px 0 10px;font-size:15px}
    #titlearea{border-bottom:1px solid #ccc;font-size:17px;padding:10px 0;}
    #contentarea{font-size:15px;margin:16px 0}
    .cell{outline:0;min-height:20px;margin:5px 0;padding:5px 0;}
    .code-cell{font-family:Menlo,Consolas,'Ubuntu Mono',Monaco,'source-code-pro',monospace;font-size:12px;}
    .latex-cell{white-space:pre-wrap;}
  </style>
  <!-- User CSS -->
  <style> .text-cell {font-size: 15px;}.code-cell {font-size: 12px;}.markdown-cell {font-size: 15px;}.latex-cell {font-size: 15px;}</style>
</head>
<body>
  <div id="nav"><div>Next: <a href='Plasma Cell Dyscrasias.html'>Plasma Cell Dyscrasias</a>, Previous: <a href='Lymphomas.html'>Lymphomas</a>, Up: <a href='index.html'>Index</a></div></div>
  <div id="titlearea">
    <h2>Myeloproliferative Neoplasms</h2>
  </div>
  <div id="contentarea"><div class="cell markdown-cell"><h1 id="general-principles">General Principles</h1>
<p>Neoplastic proliferation of <strong>myeloid-lineage</strong> cells:</p>
<ul>
<li>Granulocytes =&gt; CML</li><li>Erythrocytes =&gt; Polycythemia Vera</li><li>Megakaryocytes producing platelets =&gt; Essential Thrombocythemia</li><li>Megakaryocytes =&gt; Primary Myelofibrosis</li></ul>
<p>Causes <strong>hypercellular bone marrow</strong> and <strong>increased peripheral blood counts</strong>.<br>Increases risk of <strong>hyperuricemia and gout</strong> - high RBC turnover =&gt; increased uric acid upon removal of nucleus from mature RBCs.</p>
<p>Affects <strong>older adults</strong>, can cause splenomegaly, can progress to <strong>marrow fibrosis</strong> (which will cause cytopenias), and can progress to <strong>acute leukemia</strong></p>
<hr>
<h1 id="polycythemia-vera">Polycythemia Vera</h1>
<p>Clonal hematopoietic neoplasm of <strong>erythroid</strong> cells, strongly associated with <strong>JAK2 mutation</strong></p>
<ul>
<li><strong>Granulocytes</strong> and <strong>platelets</strong> are also <strong>increased</strong></li></ul>
<p>Symptoms are related to <strong>increased RBC mass</strong> causing <strong>hyperviscocity</strong> of the blood:</p>
<ul>
<li>Blurry vision, headache, HTN, flushed face, pruritis</li><li>Increased risk of venous thrombosis (Budd-Chiari Syndrome)</li><li>Splenomegaly, thrombosis or bleeding</li><li><strong>Low EPO level</strong> (distinguishes from reactive polycythemia)</li></ul>
<p>Hypercellular Marrow with <strong>prominent erythroid cells</strong> and <strong>atypical megakaryocytes</strong></p>
</div><div class="cell text-cell"><img src="resources/29DF868194EFB32FEF87E4152FA568B4.png" alt="Screen Shot 2016-02-20 at 9.16.27 AM.png"></div><div class="cell markdown-cell"><p>Disease Progression:</p>
<ol>
<li>Chronic Phase - indolent, 10-15 year survival</li><li>Spent phase - myelofibrosis, 2-3 year median survival</li><li>Acute leukemia - 1-2% of patients managed with phlebotomy progress to acute leukemia</li></ol>
<p>Treatment: <strong>Phlebotomy</strong> to decrease Hct to under 45%, <strong>Hydroxyurea</strong> for high risk patients, Aspirin for low risk patients</p>
<hr>
<h1 id="essential-thrombocythemia">Essential Thrombocythemia</h1>
<p>Neoplastic proliferation of <strong>platelets</strong>, associated with <strong>JAK2 mutation</strong> (but not as strongly as PV), with persistent thrombocytosis &gt; 600,000</p>
<ul>
<li>In addition to older adults, can also affect women ~30yo</li></ul>
<p>Symptoms are secondary to elevated platelets, but patients are often asymptomatic:</p>
<ul>
<li>Bleeding and thrombosis</li><li>Mild splenomegaly</li><li>No increased risk of hyperuricemia/gout</li></ul>
<p>Increased platelets in peripheral blood with some <strong>giant platelets</strong>. Increased hyperlobulated and large megakaryoctes in bone marrow.</p>
<ul>
<li>Bone marrow cellularity may be normal or only slightly increased</li></ul>
</div><div class="cell markdown-cell"><p>Disease Progression is mild, marrow fibrosis is uncommon</p>
<p>Treatment: Hydroxyurea for high risk patients (thrombosis history, old), aspirin for low risk patients</p>
<hr>
<h1 id="primary-myelofibrosis">Primary Myelofibrosis</h1>
<p>Neoplastic prolifertion of <strong>megakaryocytes</strong> associated with <strong>excess Platelet-Derived Growth Factor</strong> excretion, causing <strong>marrow fibrosis and extramedullary hematopoiesis</strong></p>
<ul>
<li>Disease progresses from proliferative to fibrotic, causing different clinical and pathological findings</li></ul>
<p>Pre-fibrotic Symptoms:</p>
<ul>
<li>Fatigue, weakness, SOB</li><li>Splenomegaly, possible hepatomegaly</li><li>Mild anemia, moderate leukocytosis and thrombocytosis</li></ul>
<p>Fibrotic Symptoms:</p>
<ul>
<li>Marked <strong>hepatosplenomegaly</strong></li><li>Increased blasts, Prominent <strong>tear drop RBCs</strong> and nucleated RBCs in blood</li></ul>
<p>Pre-fibrotic: <strong>Hypercellular</strong> marrow with increased <strong>atypical, clustered megakaryocytes</strong>; mild reticulin fiboris<br>Post-fibrotic: Marrow is replaced by collagen fibrosis</p>
</div><div class="cell text-cell"><img src="resources/5AEAD819EED8D80BC17E1B7EB61AFBCA.png" alt="Screen Shot 2016-02-20 at 9.36.39 AM.png"></div></div>
  <script>document.body.onkeyup = function(e) {
if (e.keyCode === 39) window.location.href = 'Plasma Cell Dyscrasias.html';
if (e.keyCode === 37) window.location.href = 'Lymphomas.html';
}</script>
</body>
</html>